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Abstract
Background: Making treatment decisions in anticipation of possible future incapacity is an important part of patient
participation in end-of-life decision-making. This study estimates and compares the prevalence of GP-patient end-of-life
treatment discussions and patients’ appointment of surrogate decision-makers in Italy, Spain, Belgium and the Netherlands
and examines associated factors.
Methods: A cross-sectional, retrospective survey was conducted with representative GP networks in four countries. GPs
recorded the health and care characteristics in the last three months of life of 4,396 patients who died non-suddenly.
Prevalences were estimated and logistic regressions were used to examine between country differences and country-
specific associated patient and care factors.
Results: GP-patient discussion of treatment preferences occurred for 10%, 7%, 25% and 47% of Italian, Spanish, Belgian and
of Dutch patients respectively. Furthermore, 6%, 5%, 16% and 29% of Italian, Spanish, Belgian and Dutch patients had a
surrogate decision-maker. Despite some country-specific differences, previous GP-patient discussion of primary diagnosis,
more frequent GP contact, GP provision of palliative care, the importance of palliative care as a treatment aim and place of
death were positively associated with preference discussions or surrogate appointments. A diagnosis of dementia was
negatively associated with preference discussions and surrogate appointments.
Conclusions: The study revealed a higher prevalence of treatment preference discussions and surrogate appointments in
the two northern compared to the two southern European countries. Factors associated with preference discussions and
surrogate appointments suggest that delaying diagnosis discussions impedes anticipatory planning, whereas early
preference discussions, particularly for dementia patients, and the provision of palliative care encourage participation.
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Introduction
The nature of the patient-physician relationship has changed
considerably over the last forty years with patient autonomy and
participation in decision-making increasingly recognised [1]. For
patients receiving end-of-life (EoL) care, participation includes
preparation for possible future incapacity.
The most well known form of anticipatory decision-making is an
advance directive. Advance directives are documents that outline
treatments that a patient considers acceptable in the event that he
or she can no longer communicate or that designate a surrogate
decision-maker to make treatment choices on the patient’s behalf
[2]. Research indicates that, even in the US, where advance
directives are actively promoted and legally binding, uptake
amongst the general public remains low, at around 20% [3,4].
International studies and comparisons suggest even lower uptake
[5,6].
Advance directives however are just one aspect of anticipatory
decision-making. The cornerstone of this is rather the process of
patient-physician discussion regarding EoL treatment decisions
[7]. Therefore, measures of patient-physician discussions about
treatment preferences or the informal and formal appointment of
surrogate decision-makers may be more appropriate indicators of
patients’ involvement in treatment decisions than advance
directive uptake [8,9]. Moreover, due to cross-country differences
in legal status and use of advance directives, such measures are
particularly appropriate for international comparisons [5,10].
Few studies have examined patient-physician EoL treatment
preference discussions or patients’ appointment of surrogate
decision-makers (written and verbal). Furthermore, results of these
studies are difficult to compare due to differences in study
population and question formulation. Previous studies have
focused on the discussion of specific treatments [11–13], formal
surrogate appointments (legal guardians or power of attorney)
[14,15] or on specific patient populations [11,14–16].
This study examines GP-patient discussions of medical EoL
treatment preferences and patients’ appointment of surrogate
decision-makers in Italy, Spain, Belgium and the Netherlands. The
study draws on information from representative GP sentinel
networks about patient care in the last three months of life. In the
four countries, almost all patients are registered with a GP [17]
and GPs are instrumental in the delivery and coordination of EoL
care [18–22].
Specific objectives include: to estimate and compare the
prevalence of GP-patient medical EoL treatment preference
discussions and patients’ appointment of surrogate decision-
makers in four European countries; and to examine country
specific factors associated with treatment preference discussions
and surrogate appointments.
Methods
Study Design, Setting and Population
The study follows a cross-sectional, retrospective design.
Participants from representative GP networks registered every
patient death and described the patient and care characteristics
using a standardised registration form.
In Spain, Belgium and the Netherlands, existing GP sentinel
networks, used for epidemiological surveillance, took part in the
study [18,20,23]. In Italy a network was created specifically for the
study [24]. To avoid selecting GPs with a particular interest in
EoL care, recruited GPs were not informed about the subject of
the surveillance prior to participation [24].
In Belgium and the Netherlands the networks were nationwide
and covered 1.75% and 0.8% of the population respectively. The
Spanish network operated in two autonomous communities
(Castile and Leo´n, and Valencia), covering 3.8% and 2.2% of
the respective regional populations. The Italian network operated
in nine local health districts and covered 4% of the population per
health district. GPs registered deaths (aged 18 or older) from 01/
01/2009 to 31/12/2010, apart from Spanish GPs who registered
deaths from 01/01/2010 to 31/12/2010.
A total of 6,858 deaths were recorded. To include only patients
who could have received EoL care, deaths registered as sudden
and totally unexpected (n = 2243), or for which this information
was missing (n = 97), were excluded. As the study concerns patient-
GP discussions, only patients under their GP’s care were included
(patients resident in their own or a family member’s home, or a
care/residential home). Dutch nursing home patients, cared for by
the nursing home physician, were excluded (n = 22). Patients
whose main place of residence was ‘unknown’ (n = 28) or ‘other’
(often institutions outside the GP’s care) (n = 72) were also
excluded. The final sample consisted of 4,396 deaths (Italy
n = 1,808, Spain n = 379, Belgium n = 1,556, the Netherlands
n = 653). Comparing the data with national data on non-sudden
deaths (excluding Dutch nursing home deaths in the Netherlands)
verified representativeness of all deaths (except for a slight
underrepresentation of non-sudden hospital deaths and people
under the age of 65 in Belgium, and women in the Netherlands)
[24].
Informed Consent, Patient Anonymity and Ethics
Approval
After being informed of the objectives and procedures of the
study, participating GPs gave written informed consent at the
beginning of each registration year. Strict procedures regarding
patient anonymity were employed during data collection and
entry; every patient received an anonymous reference code from
their GP and any identifying patient and GP data (such as date of
birth, postcode and GP identification number) were replaced with
aggregate categories or anonymous codes.
In Belgium the protocol of the study was approved by the
Ethical Review Board of Brussels University Hospital of the Vrije
Universiteit Brussel (2004). In Italy, ethics approval for data
collection was obtained from the Local Ethical Committee
‘Comitato Etico della Azienda U.S.L. n. 9 di Grosseto’, Tuscany
(2008). Ethical approval was not required for posthumous
collection of anonymous patient data in the Netherlands [25,26]
or Spain [27–29].
Measurement Instrument
The 2009/2010 EURO SENTI-MELC (European Sentinel
Network Monitoring End-of-Life Care) form consisted of 21
structured questions about the patient’s demographic, health, and
care characteristics in the last three months of life. Participants
were requested to include information from hospital physicians
and patient records.
Discussion of treatment preferences was determined from the
two-part question, ‘‘Did the patient ever express specific wishes
about a medical treatment that he/she would or would not want in
the final phase of life?’’ And, if yes, ‘‘Did you ever speak to the
patient about these wishes?’’ The current article focuses on the
second part of this question. With regard to surrogate decision-
maker appointments, the registration form included the item, ‘‘Did
the patient ever express a wish about who was to make decisions
regarding medical treatments or activities in his/her place in the
event he/she would no longer be able to speak for him/herself?
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The following independent variables, associated with anticipa-
tory decision making in previous studies [20,30,31], were also
collected: age; sex; cause of death; dementia diagnosis; residence in
the last year of life; place of death; GP contacts; GP provision of
palliative care (as defined by the GP); the importance of curative,
life-prolonging and palliative care (on a 5-point Likert Scale); and
whether the GP had discussed the primary diagnosis with the
patient.
Most questions included in the registration form had been used
in previous Dutch and Belgian studies [20,30,32] and had been
subjected to extensive piloting [30,33]. New questions were
developed in collaboration with all partners. The final registration
form underwent forward and backward translations from Dutch
into English, from English into Italian and Spanish, and from
Dutch into French and was piloted in each country (with 10 to 15
GPs) [24].
Data Analysis
For each country, study population characteristics were assessed
using descriptive statistics and differences between countries were
assessed using Pearson’s chi-sq tests.
Prevalence of patient-GP treatment preference discussions and
appointment of surrogate decision-makers were estimated per
country using descriptive statistics. Differences between countries
were examined using logistic regressions (controlling for study
populations characteristics which differed significantly between
countries).
Country specific factors associated with treatment preference
discussions and surrogate appointments were examined through
univariate and multivariable logistic regressions. Associations
significant in univariate analyses were included in multivariable
models. Stepwise backwards procedures were used (criteria for
entry p,0.05 and for removal p.0.1) and residuals examined.
Continuous variables were transformed to be categorical (age,
number of GP contacts). Cause of death was re-categorised as
cancer or non-cancer. Furthermore, the treatment aims were
dichotomised by combining ‘‘important’’ and ‘‘very important’’ in
one category and other responses in another. All data analysis was
carried out in SPSS version 18.
Results
Characteristics of the Study Population
Patient and care characteristics are shown in Table 1. The
mean age of death was 80, 81, 79 and 77 for Italian, Spanish,
Belgian and Dutch patients respectively. Although characteristics
varied between countries, the most common cause of death was
cancer (37–52%). Just under a third of patients in Italy, Spain and
Belgium suffered from dementia (29–31%), compared with 13% of
Dutch patients.
Approximately half of the Italian, Spanish and Dutch patients
died at home (44–50%), compared with under a quarter of Belgian
patients (24%). 24–32% of patients in the last week of life, and 8–
20% of patients in the second and third months before death had
no contact with their GP. GPs however provided palliative care to
51–65% of patients.
Curative treatment was important in the care of 18–31% of
patients, prolonging life in 24–49% of cases and palliative care in
42–65% of cases. GPs had discussed the primary diagnosis with
49% of Italian, 50% of Spanish, 60% of Belgian and 78% of
Dutch patients.
Patient-GP Discussion of Medical EoL Treatment
Preferences and Patient Appointment of a Surrogate
Decision-maker
Table 2 shows the prevalence of treatment preference
discussions and surrogate decision-maker appointments in the
four countries.
A minority of patients from all countries (10–31%), except the
Netherlands (52%), had either discussed treatment preferences or
appointed a surrogate decision-maker. GP-patient discussion of
treatment preferences had taken place with 10% of Italian, 7% of
Spanish, 25% of Belgian and 47% of Dutch patients. Further-
more, 6% of Italian, 5% of Spanish, 16% of Belgian and 29% of
Dutch patients had appointed (either verbally or in writing) a
surrogate decision-maker.
Multivariable logistic regressions revealed a strong association
between country and both treatment preference discussions and
surrogate appointments. The odds of discussing treatment
preferences with a GP were over six times higher for a Dutch
patient, and almost four times higher for a Belgian patient,
compared with an Italian patient. Similarly, the odds of appointing
a surrogate decision-maker were over four times higher for a
Dutch patient, and almost three times higher for a Belgian patient,
than for an Italian patient. There were no significant differences in
the odds of GP-patient discussion of treatment preferences or
appointment of surrogate decision-makers between Italy and
Spain. Surrogate appointment was entirely verbal in Italy and
Spain and most frequently verbal in the Netherlands and Belgium.
Factors Associated with Discussion of a Medical EoL
Treatment Preference
Table 3 shows the factors associated with GP-patient discussion
of EoL treatment preferences in univariate and multivariable
analyses. The multivariable models revealed country specific
associations. Diagnosis of dementia was negatively associated with
treatment preference discussions in Belgium and the Netherlands.
Palliative care unit (PCU) deaths were positively associated with
preference discussions compared with hospital deaths in Belgium.
Furthermore, in Belgium, more frequent GP contact in the last
week of life was positively associated with preference discussions,
and in both Belgium and the Netherlands more frequent contact
in the second and third months before death was positively
associated with preference discussions. GP provision of palliative
care was positively associated with preference discussions in all
countries and the recognition of palliative care as an important/
very important treatment aim was positively associated with
preference discussions in Belgium. Previous GP-patient discussion
of the primary diagnosis was positively associated with preference
discussions in all countries.
Factors Associated with Patient Appointment of a
Surrogate Decision-maker
The factors associated with surrogate decision-maker appoint-
ments in univariate and multivariable analyses are presented in
Table 4. Country specific associations were revealed in the
multivariable models. Surrogate appointments were negatively
associated with male patients in the Netherlands. In Spain PCU/
hospice deaths were positively associated with surrogate appoint-
ments compared with hospital deaths.
More frequent patient-GP contact in the last week before death
was positively associated with surrogate appointments for Belgium
and the Netherlands. Furthermore, the importance of palliative
care was positively associated with surrogate appointments in
Belgium, the Netherlands and Spain.
End-of-Life: Preference Discussions and Surrogates
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Previous discussion of the primary diagnosis between the patient
and the GP was positively associated with surrogate appointments
in all four countries.
Discussion
These data reveal that a minority of patients from all countries,
with the exception of the Netherlands, had either discussed
treatment preferences or appointed a surrogate decision-maker.
Furthermore, there are important cross-country differences in
prevalence of discussions and surrogate appointments, which were
highest in the Netherlands, followed by Belgium, with no
significant differences between Spain and Italy.
The single most important patient or care factor associated with
treatment preferences discussions in all countries, and with
surrogate appointments in the Netherlands and Italy, was prior
GP-patient discussion of the primary diagnosis.
Table 1. Patients’ personal and care characteristics (n = 4,396)a.
IT ES BE NL p valueb
n=1808 n=379 n=1556 n=653
n (%) n (%) n (%) n (%)
Age ,= 64 227 (13) 43 (11) 214 (14) 119 (18) ,0.001
65–74 293 (16) 47 (12) 212 (14) 125 (19)
75–84 556 (31) 124 (33) 516 (33) 198 (30)
85. 732 (40) 165 (44) 602 (39) 211 (32)
Mean 79.6 80.5 79.0 77.0
Sex Male 844 (47) 202 (53) 712 (46) 304 (47) 0.075
Female 964 (53) 177 (47) 840 (54) 342 (53)
Cause of death Cancer 820 (46) 147 (39) 581 (37) 339 (52) ,0.001
Cardiovascular disease 371 (21) 63 (17) 226 (15) 101 (16)
Respiratory disease 129 (7) 53 (14) 168 (11) 50 (8)
Diseases of the nervous
system
104 (6) 17 (5) 113 (7) 20 (3)
Stroke 177(10) 40 (11) 103 (7) 28 (4)
Other 163 (9) 56 (15) 363 (23) 112 (17)
Patient diagnosed with dementia 520 (29) 112 (31) 478 (31) 84 (13) ,0.001
Place of death Hospital 697 (39) 124 (33) 556 (36) 171 (28) ,0.001
Residential or care home 163 (9) 46 (12) 479 (31) 112 (18)
Home (inclu. service flat) or
with family
842 (47) 186 (50) 365 (24) 273 (44)
Palliative care unit/hospice 100 (6) 16 (4) 147 (10) 65 (10)
(Other n = 41)c
Number of GP-patient contacts
in the week before death
0 475 (26) 123 (32) 366 (24) 162 (25) ,0.001
1 or 2 786 (43) 149 (39) 768 (49) 173 (26)
3. 547 (30) 107 (28) 422 (27) 318 (49)
Number of GP-patient contacts
in the second and third month
before death
0 145 (8) 73 (19) 127 (8) 130 (20) ,0.001
1 or 2 972 (54) 222 (59) 1227 (79) 369 (57)
3. 691 (38) 84 (22) 202 (13) 154 (24)
GP provided palliative care 995 (55) 232 (65) 787 (51) 374 (60) ,0.001
Treatment aim important or
very important
Curative treatment 322 (18) 91 (24) 468 (31) 141 (24) ,0.001
Life prolongation 747 (42) 91 (24) 573 (39) 165 (28) ,0.001
Palliative care 749 (42) 182 (48) 733 (51) 390 (65) ,0.001
GP and patient had discussed
the primary diagnosis
880 (49) 172 (50) 932 (60) 498 (78) ,0.001
a% of missing observations ranged from 0.3–4.5%.
btest of association: Pearson’s chi-sq.
cnot included in statistical analyses - Patients for whom the main place of care in the last year of life was reported as ‘‘other’’ and Dutch patients in nursing homes were
excluded from the analysis for reasons described in the methods section.
doi:10.1371/journal.pone.0057965.t001
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Differences between Countries
There are notable differences between northern and southern
European countries with a lower prevalence of treatment
preference discussions and surrogate appointments in Italy and
Spain. Considering the strong association between discussion of
the primary diagnosis and both preference discussions and
surrogate appointments, these cross-country differences are linked
to lower levels of primary diagnosis discussion in Italy and Spain
compared with the Netherlands and Belgium. Previous studies
have also reported limited disclosure [9,31,34,35] and discussion
of EoL treatment preferences [11,36] in the two southern
European countries.
Men˜aca et al [9], in a review of EoL care and culture in Italy,
Spain and Portugal, highlighted the influence of Catholicism on
disclosure of diagnoses and prognoses. Catholic teaching permits
the gradual disclosure of ‘‘truth’’ to terminal patients in a way that
does not destroy hope [37]. Men˜aca [9] also found that although
advance directives have a strong legal status in Spain (in contrast
to Italy) in practice physicians are more guided by the principle of
beneficence [9]. In Italy, it has been suggested that physicians’
concern about distress caused by EoL treatment discussions leads
them to delay or avoid such discussions [37].
Belgium, in contrast, although nominally Catholic, has more in
common with the Netherlands. The process of legalization of
euthanasia in both countries engendered open public debate on
EoL issues [5,38]. A higher frequency of anticipatory decision-
making in the Netherlands and Belgium may therefore be
expected considering the importance of self-determination and
the open discussion of death and dying. This is especially true in
the Netherlands, where patients prioritize autonomy and control
in the dying process [39,40]. Cross-country studies have repeatedly
found that Dutch physicians’ more frequently discuss EoL issues
than their European counterparts [13,41,42].
Family members’ opposition to full-disclosure of primary
diagnosis, the so called ‘‘conspiracy of silence’’, has also been said
to contribute to low levels of disclosure in both Italy and Spain [9].
A lack of disclosure and subsequent EoL discussions may also
impact patients’ appointment of surrogate decision-makers.
Equally, such appointments may be deemed unnecessary if family
members are considered de facto proxies. This may contribute to
the lower prevalence of surrogate appointments compared with
preference discussions in all countries, particularly in Spain and
Italy, which are often seen as more family orientated.
An additional consideration concerns patients’ wishes for
information. A systematic review of EoL communication reported
that studies from northern European countries report higher levels
of desired information amongst patients than studies from the
south of Europe [43]. Although the desire for diagnosis and
prognosis information may not be as common amongst patients
and the general public in Italy and Spain compared to northern
European countries; in general, the proportion reported to prefer
full disclosure is still greater than the proportion that receives full
disclosure in clinical practice [9,44].
A GP’s responsibility for EoL care also varies between the four
countries. In the Netherlands there is a strong focus on GP EoL
care provision: GPs are primarily responsible for generalist EoL
care provision and have easy access to palliative care guidelines
and consultation [45,46]. In Belgium, Spain and Italy however
provision is more often shared with palliative care home teams
[21,47,48]. Furthermore GPs have a ‘gatekeeper’ role (coordinat-
ing all referrals to specialist services) in the Netherlands and Spain,
but not in Belgium and Italy.
A further explanation for the strong cross-country differences
lies in the amount of palliative care training physicians receive. A
survey of physicians from Belgium, Denmark, Italy, the Nether-
lands, Sweden and Switzerland revealed that the percentage of
physicians who had undertaken formal palliative care training was
lowest in Italy and highest in the Netherlands [49]. Palliative care
training may improve EoL communication skills and may contain
specific EoL communication training.
Country Specific Factors Associated with Treatment
Preference Discussions and Surrogate Appointments
A number of patient and care characteristics were associated
with treatment preferences discussions. As mentioned previously
GP-patient discussion of the primary diagnosis was strongly
associated with both treatment preferences and surrogate
appointments. In addition, dementia diagnosis was associated
with less frequent discussion of treatment preferences in Belgium
and the Netherlands. Timely discussions are a priority for patients
with dementia. A related issue is the early diagnosis of dementia.
Research shows that 50–66% of patients with dementia are not
diagnosed with the condition by primary care physicians [50]. GPs
are recommended to begin preference discussions as soon as
mental capacity decline is detected.
Frequency of contact with GPs, GP provision of palliative care
and the importance of palliative care as a treatment aim were also
associated with preference discussions and surrogate appoint-
ments.
Palliative care unit and home deaths were associated with
treatment preference discussions in Belgium. This may reflect an
emphasis on palliative home care in Belgium [5] and discussion of
preferences in the palliative care sector. In Spain, surrogate
appointment was associated with PCU and hospice deaths.
Indeed, for Spain, ‘place of death’ was the factor most strongly
associated with surrogate appointments in the multivariable
model; suggesting that, for Spanish patients, surrogate appoint-
ment is specifically related to specialist inpatient palliative care.
Interestingly, in the Netherlands patient surrogate appointment
was more frequent amongst female patients. This may indicate a
greater reluctance amongst GPs to discuss surrogate appointments
with male patients or of male patients to assign decision-making
responsibilities. Men are also more likely to have a living partner,
so may feel less need to appoint a surrogate decision-maker [51].
Why this should only be significant in the Netherlands and not the
other countries is, however, unclear.
Strengths and Limitations
This is the first population-based study to estimate the
prevalence of medical EoL treatment discussions and patients’
appointment of surrogates in the Netherlands, Belgium, Italy and
Spain. The use of the same study design amongst representative
GP sentinel networks in each country provided robust and
comparable data. Bias was avoided by selecting GPs with no
specific interest in EoL care. As most people in each country are
registered with a GP, representative samples of non-sudden deaths
were obtained. A strength of the retrospective design is that a
representative sample of the palliative care population could be
identified.
The study was, however, subject to a number of limitations.
Although GPs completed registration forms on a weekly basis,
there may have been some recall bias. In addition, GPs may have
provided socially desirable answers especially concerning items
that reflect on their own care competencies; particularly high levels
of GP provision of palliative care for example were reported in all
four countries. Furthermore, the study reports the discussion of
treatment preferences according to the GP. Patients and
physicians may differ in their perception of what constitutes the
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‘‘discussion’’ of treatment preferences and patients may have
discussed preferences with other health professionals.
The Spanish and Italian sentinel networks were not nationwide,
although they were representative of the areas they covered (Italy
was representative for the largest statistical regions). Dutch nursing
home residents were excluded from analyses and there was a slight
underrepresentation of non-sudden hospital deaths and people
under the age of 65 in Belgium and a slight underrepresentation of
females in the Netherlands. Some sudden deaths in hospitals may
also have been missed by GPs in Spain and Italy. However, due to
a lack of national data on place of death, this could not be tested.
The survey also relied on GPs to report care in other settings,
although GPs were asked to maximize information from other
sources. In addition, GPs’ characteristics were unavailable;
preventing examination of associations with GP characteristics.
Finally, the study only examines the prevalence of treatment
preference discussions and surrogate appointments and some
associated factors. Further qualitative research on the patient-
physician communication process may help in understanding the
complex reasons for between country differences.
Conclusions
Discussion of both medical EoL treatment preferences and
surrogate appointments were highest in the Netherlands, followed
by Belgium, with no significant differences between Spain and
Italy. A number of factors related to the discussion of the primary
diagnosis, patient’s mental capacity and specialist or generalist
palliative care were associated with treatment discussions and
surrogate appointments.
These findings suggest that the process of planning for the EoL
often starts with the discussion of the primary diagnosis: if avoided
or delayed, opportunities for patient participation in decision-
making may be missed. Communication training for physicians
can help change attitudes towards diagnosis disclosure [52,53].
Ideally training would also highlight the right of a patient not to
receive such information if he or she so wishes; such a preference
however must be stated by the patient and not assumed a priori by
the physician.
Furthermore, early preference discussions for all patients,
particularly those with dementia or cognitive decline, and the
provision of palliative care support patients’ participation in EoL
decision-making.
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